The Europe Joint Pain Injections Market should witness market growth of 7.2% CAGR during the forecast period (2022-2028).
Hyaluronic acid injections are used to restore the lost lubricant in the event of osteoarthritis, a kind of arthritis in which the hyaluronic acid that serves as natural lubrication in the joint degrades. Joint pain injections are typically administered directly into the joints to ensure optimal effectiveness.
A local anesthetic and medication are administered to the patients during the facet joint injection, a minimally invasive technique, to numb the facet joint and relieve discomfort. The healthcare sector is expected to experience significant growth in the coming years, mostly due to the development of 'value-based'care models.
This development foreshadows the market's expansion for joint pain injections, which will double in size over the years. The primary driver of facet joint injections during the projection period is likely to be the rising desire for non-surgical therapies. Also, increasing emphasis on efficient pain management may significantly contribute to the overall development of the joint pain injections Market during the evaluation period. Pain specialists use facet joint injections to treat chronic spinal diseases effectively, and they continue to be one of the market players' primary sources of income.
Falls and fractures were the most prevalent and severe health problems that older individuals in England encountered. The human cost includes misery, agony, damage, loss of autonomy, loss of self-assurance, and even death. As a result, health services are both expensive and abundant. According to the Falls and Fracture Consensus Statement, published by Public Health England and the National Falls Prevention Coordination Group in January 2017, the total cost of fragility fractures in the United Kingdom is estimated to be £4.4 billion, of which £1.1 billion is allocated to social care. Fractures of the hip account for roughly two billion dollars of this total.This increases the incidence of joint pains among fracture sufferers, raising the need for joint pain injections in Europe.
The Germany market dominated the Europe Joint Pain Injections Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $648.5 Million by 2028. The UK market is exhibiting a CAGR of 6.4% during (2022-2028). Additionally, The France market would experience a CAGR of 8% during (2022-2028).
Based on Injection Type, the market is segmented into Interleukin Inhibitors, Hyaluronic Acid Injections, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Joint Type Channel, the market is segmented into Knee & Ankle, Shoulder & Elbow, Hip Joint, Facet Joints of the Spine, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioventus Inc., Pacira BioSciences, Inc., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc., Anika Therapeutics, Inc., Zimmer Biomet Holdings, Inc., Eli Lilly And Company, Ferring Holdings SA, and Sanofi S.A.
Hyaluronic acid injections are used to restore the lost lubricant in the event of osteoarthritis, a kind of arthritis in which the hyaluronic acid that serves as natural lubrication in the joint degrades. Joint pain injections are typically administered directly into the joints to ensure optimal effectiveness.
A local anesthetic and medication are administered to the patients during the facet joint injection, a minimally invasive technique, to numb the facet joint and relieve discomfort. The healthcare sector is expected to experience significant growth in the coming years, mostly due to the development of 'value-based'care models.
This development foreshadows the market's expansion for joint pain injections, which will double in size over the years. The primary driver of facet joint injections during the projection period is likely to be the rising desire for non-surgical therapies. Also, increasing emphasis on efficient pain management may significantly contribute to the overall development of the joint pain injections Market during the evaluation period. Pain specialists use facet joint injections to treat chronic spinal diseases effectively, and they continue to be one of the market players' primary sources of income.
Falls and fractures were the most prevalent and severe health problems that older individuals in England encountered. The human cost includes misery, agony, damage, loss of autonomy, loss of self-assurance, and even death. As a result, health services are both expensive and abundant. According to the Falls and Fracture Consensus Statement, published by Public Health England and the National Falls Prevention Coordination Group in January 2017, the total cost of fragility fractures in the United Kingdom is estimated to be £4.4 billion, of which £1.1 billion is allocated to social care. Fractures of the hip account for roughly two billion dollars of this total.This increases the incidence of joint pains among fracture sufferers, raising the need for joint pain injections in Europe.
The Germany market dominated the Europe Joint Pain Injections Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $648.5 Million by 2028. The UK market is exhibiting a CAGR of 6.4% during (2022-2028). Additionally, The France market would experience a CAGR of 8% during (2022-2028).
Based on Injection Type, the market is segmented into Interleukin Inhibitors, Hyaluronic Acid Injections, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Joint Type Channel, the market is segmented into Knee & Ankle, Shoulder & Elbow, Hip Joint, Facet Joints of the Spine, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioventus Inc., Pacira BioSciences, Inc., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc., Anika Therapeutics, Inc., Zimmer Biomet Holdings, Inc., Eli Lilly And Company, Ferring Holdings SA, and Sanofi S.A.
Scope of the Study
By Injection Type
- Interleukin Inhibitors
- Hyaluronic Acid Injections
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Others
By Joint Type
- Knee & Ankle
- Shoulder & Elbow
- Hip Joint
- Facet Joints of the Spine
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Bioventus Inc.
- Pacira BioSciences, Inc.
- AbbVie, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
- Anika Therapeutics, Inc.
- Zimmer Biomet Holdings, Inc.
- Eli Lilly And Company
- Ferring Holdings SA
- Sanofi S.A.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Joint Pain Injections Market, by Injection Type
1.4.2 Europe Joint Pain Injections Market, by Distribution Channel
1.4.3 Europe Joint Pain Injections Market, by Joint Type
1.4.4 Europe Joint Pain Injections Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Joint Pain Injections Market by Injection Type
3.1 Europe Interleukin Inhibitors Market by Country
3.2 Europe Hyaluronic Acid Injections Market by Country
3.3 Europe Others Market by Country
Chapter 4. Europe Joint Pain Injections Market by Distribution Channel
4.1 Europe Drug Stores & Retail Pharmacies Market by Country
4.2 Europe Hospital Pharmacies Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Joint Pain Injections Market by Joint Type
5.1 Europe Knee & Ankle Market by Country
5.2 Europe Shoulder & Elbow Market by Country
5.3 Europe Hip Joint Market by Country
5.4 Europe Facet Joints of the Spine Market by Country
5.5 Europe Others Market by Country
Chapter 6. Europe Joint Pain Injections Market by Country
6.1 Germany Joint Pain Injections Market
6.1.1 Germany Joint Pain Injections Market by Injection Type
6.1.2 Germany Joint Pain Injections Market by Distribution Channel
6.1.3 Germany Joint Pain Injections Market by Joint Type
6.2 UK Joint Pain Injections Market
6.2.1 UK Joint Pain Injections Market by Injection Type
6.2.2 UK Joint Pain Injections Market by Distribution Channel
6.2.3 UK Joint Pain Injections Market by Joint Type
6.3 France Joint Pain Injections Market
6.3.1 France Joint Pain Injections Market by Injection Type
6.3.2 France Joint Pain Injections Market by Distribution Channel
6.3.3 France Joint Pain Injections Market by Joint Type
6.4 Russia Joint Pain Injections Market
6.4.1 Russia Joint Pain Injections Market by Injection Type
6.4.2 Russia Joint Pain Injections Market by Distribution Channel
6.4.3 Russia Joint Pain Injections Market by Joint Type
6.5 Spain Joint Pain Injections Market
6.5.1 Spain Joint Pain Injections Market by Injection Type
6.5.2 Spain Joint Pain Injections Market by Distribution Channel
6.5.3 Spain Joint Pain Injections Market by Joint Type
6.6 Italy Joint Pain Injections Market
6.6.1 Italy Joint Pain Injections Market by Injection Type
6.6.2 Italy Joint Pain Injections Market by Distribution Channel
6.6.3 Italy Joint Pain Injections Market by Joint Type
6.7 Rest of Europe Joint Pain Injections Market
6.7.1 Rest of Europe Joint Pain Injections Market by Injection Type
6.7.2 Rest of Europe Joint Pain Injections Market by Distribution Channel
6.7.3 Rest of Europe Joint Pain Injections Market by Joint Type
Chapter 7. Company Profiles
7.1 Bioventus Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Product Launches and Product Expansions:
7.2 Pacira BioSciences, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.2.4 Recent strategies and developments:
7.2.4.1 Acquisition and Mergers:
7.3 AbbVie, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Trails and Approvals:
7.4 Teva Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.6 Anika Therapeutics, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Zimmer Biomet Holdings, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.8 Eli Lilly And Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Ferring Holdings SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research and Development Expense
7.10. Sanofi S.A.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
Companies Mentioned
- Bioventus Inc.
- Pacira BioSciences, Inc.
- AbbVie, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
- Anika Therapeutics, Inc.
- Zimmer Biomet Holdings, Inc.
- Eli Lilly And Company
- Ferring Holdings SA
- Sanofi S.A.
Methodology
LOADING...
